Juro Sciences development program SFG-02 was awarded the R&D grant from “the Japan Agency for Medical Research and Development (AMED) strengthening program for pharmaceutical startup ecosystem”.

Link: https://www.amed.go.jp/koubo/19/02/1902C_00047.html (Japanese)

About AMED strengthening program for pharmaceutical startup ecosystem:

https://www.amed.go.jp/content/000121880.pdf (English brochure, published in 2023)

About Juro Sciences:

Juro Sciences is a biopharmaceutical company dedicated to developing innovative therapies for underactive bladder (UAB). Leveraging cutting-edge science and a patient-centric approach, Juro Sciences is committed to improving  quality of life for individuals affected by UAB.

About SFG-02:

SFG-02 is a novel small molecule enzyme inhibitor with a transformative non-oral formulation, being developed for the treatment of UAB. Multiple preclinical studies demonstrated significant selectivity to the molecular target and optimal efficacy in animal models of UAB. Nonclinical toxicology and ADME data support IND filing and initiation of phase 1 study in healthy volunteers.

For media inquiries or further information about Juro Sciences and SFG-02, please contact: info@sfgsci.com